 |
AgomAb Therapeutics
Last updated: April 19, 2024
CEO Tim Knotnerus
Country: Belgium | Funding: $237M (+)
Website: https://agomab.com/
AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
Website: https://agomab.com/
AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
